First line treatment options for advanced triple negative breast cancer (TNBC), particularly PD L1 positive disease, remain limited, with modest durability of response to current chemo immunotherapy regimens.
Key evidence
In phase 2 trial published in The New England Journal of Medicine, combining sacituzumab govitecan with pembrolizumab significantly improved progression free survival compared with chemotherapy plus pembrolizumab in untreated PD L1 positive advanced TNBC, alongside higher objective response rates and manageable toxicity.
Clinical or research implications
This support antibody drug conjugate immunotherapy combinations a new first line strategy in TNBC, potentially redefining standard care.
Which biomarkers best identity TNBC patients who will benefit most from this combination?
MBH/AB